Regulatory Guidance forDeveloping Technologies.

Our attorneys bring deep healthcare and FDA regulatory knowledge to the questions that arise as technology reshapes how care is delivered, how health data moves, and how products reach the market.

The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.

For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us

Quick Links

Wilson Sonsini secured a jury trial win for Google in a case alleging misuse of advertising technology.

Click for additional details.

Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

News and Featured Insights

News Articles

Rob Ishii Named 2026 M&A Advisor “Legal Advisor of the Year” Finalist

News Articles

Law360 Article: “Contact Lens Rule’s Evolution Steers FTC Guidance Program”

Alerts

California Enacts Over Two Dozen Key Privacy and AI Bills into Law in 2026 Legislative Session

Leading Matters

Client Highlights

Wilson Sonsini Advises TypeSafe AI on $870 Million Series A Led by a16z

On October 9, 2026, TypeSafe AI, a company building machine-native AI models, announced it raised a $870 million Series A at a $7.5 billion valuation led by a16z. Sequoia Capital, existing investor DCVC, and other angel investors also participated in the round. Wilson Sonsini Goodrich & Rosati advised TypeSafe AI on the transaction.

Learn More

Client Highlights

Wilson Sonsini Advises Vesta on $30 Million Series B

On October 8, 2026, Vesta, an AI-native loan origination system for mortgage lenders, announced a $30 million Series B funding led by Conversion Capital. Three Vesta customers, New American Funding, Pennymac, and nbkc bank, also invested, as did Citi Ventures, FirstKey Mortgage, and Navitas Capital. Existing investors Andreessen Horowitz, Zigg Capital, and Parker89, First American Financial's venture arm, also participated. Wilson Sonsini Goodrich & Rosati advised Vesta on the transaction.

Learn More

Client Highlights

Firm Advises Voltus on Oversubscribed $225 Million Series D

On October 8, 2026, Voltus, a leading distributed energy resource platform, announced it raised $225 million in an oversubscribed Series D financing round. Generation Investment Management led the round alongside co-leads Activate Capital and Vitol. Other investors include Broadscale Group, Climate Investment, NGP, Ajax Strategies, and All Aboard Fund. Wilson Sonsini Goodrich & Rosati advised Voltus on the transaction.

Learn More

Client Highlights

Wilson Sonsini Advises Atrium Therapeutics on Patent Matters Related to $50 Million Private Placement

On October 8, 2026, Atrium Therapeutics, a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, announced that it has entered into a securities purchase agreement with a group of leading institutional investors for a private placement financing. The financing is expected to result in aggregate gross proceeds of approximately $50 million, before deducting placement agent fees and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Atrium Therapeutics on patent matters related to the transaction.

Learn More

Client Highlights

Wilson Sonsini Advises Catalyst on $30 Million Seed Funding

On October 8, 2026, Catalyst, an artificial intelligence (AI) trading start-up, announced it has raised a $30 million seed round led by Sequoia Capital. Additional investors include Jump Trading, PeakXV, Lux Capital, AntiFund, Coinbase, and Premji Invest. Wilson Sonsini Goodrich & Rosati advised Catalyst on the transaction.

Learn More

Client Highlights

Wilson Sonsini Advises Oratomic on $475 Million Series B Financing

On October 8, 2026, Oratomic, a neutral atom quantum computing company focused on building the world’s first utility-scale fault-tolerant quantum computers, announced that it raised $475 million in its Series B round, raising its valuation to $5.4 billion and bringing the company’s total funding raised to date to $775 million. The funding round was co-led by ARCH Venture Partners, Spark Capital, Khosla Ventures, Index Ventures, General Catalyst, and Bezos Expeditions. Wilson Sonsini Goodrich & Rosati advised Oratomic on the transaction.

Learn More

See More Leading Matters

The Life Sciences Report – June 2026

This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.